Development of a Trispecific Antibody Designed to Simultaneously and Efficiently Target Three Different Antigens on Tumor Cells

Molecular Pharmaceutics

Volumn 12, Issue 9, 2015, Pages 3490-3501

  Dimasi, Nazzareno ^a   Fleming, Ryan ^a   Hay, Carl ^a   Woods, Rob ^a   Xu, Linda ^a   Wu, Herren ^a   Gao, Changshou ^a  

^a MEDIMMUNE   (United States)

Author keywords

analytical ultracentrifugation; differential scanning calorimetry; EphA2; EphA4; EphB4; trispecific antibody; tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR A4; EPHRIN RECEPTOR B4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EPHA2; MONOCLONAL ANTIBODY EPHA4; MONOCLONAL ANTIBODY EPHB4; UNCLASSIFIED DRUG; ANTIGEN; PROTEIN BINDING;

ADENOCARCINOMA CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BIOCHEMISTRY; BIOPHYSICS; CARCINOMA CELL LINE; CELL ASSAY; CONTROLLED STUDY; CYTOPLASM; DRUG BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MAMMAL CELL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SEDIMENTATION RATE; STEREOSPECIFICITY; THERMOSTABILITY; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DESIGN; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PROSTATIC NEOPLASMS; SURFACE PLASMON RESONANCE; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG DESIGN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTOR, EPHA2; RECEPTOR, EPHA4; RECEPTOR, EPHB4; SURFACE PLASMON RESONANCE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941052948     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00268     Document Type: Article

References (36)

1. Al-Ejeh, F.; Offenhäuser, C.; Lim, Y. C.; Stringer, B. W.; Day, B. W.; Boyd, A. W. Eph family co-expression patterns define unique clusters predictive of cancer phenotype Growth Factors 2014, 32, 254-264 10.3109/08977194.2014.984807
2. Boyd, A. W.; Bartlett, P. F.; Lackmann, M. Therapeutic targeting of EPH receptors and their ligands Nat. Rev. Drug Discovery 2014, 13, 39-62 10.1038/nrd4175
3. Gale, N. W.; Holland, S. J.; Valenzuela, D. M. et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis Neuron 1996, 17, 9-19 10.1016/S0896-6273(00)80276-7
4. Surawska, H.; Ma, P. C.; Salgia, R. The role of ephrins and Eph receptors in cancer Cytokine Growth Factor Rev. 2004, 16, 419-433 10.1016/j.cytogfr.2004.09.002
5. Ireton, R. C.; Chen, J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics Curr. Cancer Drug Targets 2005, 5, 149-157 10.2174/1568009053765780
6. Iiizumi, M.; Hosokawa, M.; Takehara, A.; Chung, S.; Nakamura, T.; Katagiri, T.; Eguchi, H.; Ohigashi, H.; Ishikawa, O.; Nakamura, Y.; Nakagawa, H. EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth Cancer Sci. 2006, 97, 1211-1216 10.1111/j.1349-7006.2006.00313.x
7. Ferguson, B. D.; Tretiakova, M. S.; Lingen, M. W.; Gill, P. S.; Salgia, R. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies-implications for solid tumors and potential for therapeutic inhibition Growth Factors 2014, 32, 202-206 10.3109/08977194.2014.980904
8. Ferguson, B. D.; Liu, R.; Rolle, C. E.; Tan, Y. H.; Krasnoperov, V.; Kanteti, R.; Tretiakova, M. S.; Cervantes, G. M.; Hasina, R.; Hseu, R. D.; Iafrate, A. J.; Karrison, T.; Ferguson, M. K.; Husain, A. N.; Faoro, L.; Vokes, E. E.; Gill, P. S.; Salgia, R. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target PLoS One 2013, 7, e67668 10.1371/journal.pone.0067668
9. Liu, R.; Ferguson, B. D.; Zhou, Y.; Naga, K.; Salgia, R.; Gill, P. S.; Krasnoperov, V. EphB4 as a therapeutic target in mesothelioma BMC Cancer 2013, 13, 269 10.1186/1471-2407-13-269
10. Hasina, R.; Mollberg, N.; Kawada, I.; Mutreja, K.; Kanade, G.; Yala, S. et al. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers Cancer Res. 2013, 73, 184-194 10.1158/0008-5472.CAN-12-0915
11. Kumar, S. R.; Singh, J.; Xia, G.; Krasnoperov, V.; Hassanieh, L.; Ley, E. J.; Scehnet, J.; Kumar, N. G.; Hawes, D.; Press, M. F.; Weaver, F. A.; Gill, P. S. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer Am. J. Pathol. 2006, 169, 279-293 10.2353/ajpath.2006.050889
12. Kumar, S. R.; Masood, R.; Spannuth, W. A.; Singh, J.; Scehnet, J.; Kleiber, G.; Jennings, N.; Deavers, M.; Krasnoperov, V.; Dubeau, L.; Weaver, F. A.; Sood, A. K.; Gill, P. S. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome Br. J. Cancer 2007, 96, 1083-1091 10.1038/sj.bjc.6603642
13. Yang, N. Y.; Pasquale, E. B.; Owen, L. B.; Ethell, I. M. The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization J. Biol. Chem. 2006, 281, 32574-3286 10.1074/jbc.M604338200
14. Rougier, P.; Lepère, C. Metastatic Colorectal Cancer: First- and Second-Line Treatment in 2005 Semin. Oncol. 2005, 32, 15-20 10.1053/j.seminoncol.2005.07.020
15. Hurwitz, H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer Clin. Colorectal Cancer 2004, 4, S62-S68 10.3816/CCC.2004.s.010
16. Hurwitz, H. I.; Fehrenbacher, L.; Hainsworth, J. D.; Heim, W.; Berlin, J.; Holmgren, E.; Hambleton, J.; Novotny, W. F.; Kabbinavar, F. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J. Clin. Oncol. 2005, 23, 3502-3508 10.1200/JCO.2005.10.017
17. Kabbinavar, F. F.; Hambleton, J.; Mass, R. D.; Hurwitz, H. I.; Bergsland, E.; Sarkar, S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J. Clin. Oncol. 2005, 23, 3706-3712 10.1200/JCO.2005.00.232
18. Kabbinavar, F. F.; Schulz, J.; McCleod, M.; Patel, T.; Hamm, J. T.; Hecht, J. R.; Mass, R.; Perrou, B.; Nelson, B.; Novotny, W. F. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J. Clin. Oncol. 2005, 23, 3697-3705 10.1200/JCO.2005.05.112
19. Tolstrup, A. B.; Frandsen, T. P.; Bregenholt, S. Development of recombinant human polyclonal antibodies for the treatment of complex human diseases Expert Opin. Biol. Ther. 2006, 9, 905-912 10.1517/14712598.6.9.905
20. Uno, T.; Takeda, K.; Kojima, Y.; Yoshizawa, H.; Akiba, H.; Mittler, R. S. et al. Eradication of established tumors in mice by a combination antibody-based therapy Nat. Med. 2006, 12, 693-698 10.1038/nm1405
21. Leonard, J. P.; Coleman, M.; Ketas, J.; Ashe, M.; Fiore, J. M.; Furman, R. R. et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkins lymphoma J. Clin. Oncol. 2005, 23, 5044-5051 10.1200/JCO.2005.13.821
22. Strauss, S. J.; Morschhauser, F.; Rech, J.; Repp, R.; Solal-Celigny, P.; Zinzani, P. et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkins lymphoma J. Clin. Oncol. 2006, 24, 3880-3886 10.1200/JCO.2006.05.6291
23. Ye, D.; Mendelsohn, J.; Fan, Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225 Oncogene 1999, 18, 731-738 10.1038/sj.onc.1202319
24. Kawaguchi, Y.; Kono, K.; Mimura, K.; Mitsui, F.; Sugai, H.; Akaike, H.; Fujii, H. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma Br. J. Cancer 2007, 97, 494-501 10.1038/sj.bjc.6603885
25. Farid, S. S. Process economics of industrial monoclonal antibody manufacture J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 848, 8-18 10.1016/j.jchromb.2006.07.037
26. Spiess, C.; Carter, P. J. Alternative molecular formats and therapeutic applications for bispecific antibodies Mol. Immunol. 2015, 10.1016/j.molimm.2015.01.003
27. Dimasi, N.; Gao, C.; Fleming, R.; Yao, X. T.; Shirinian, L.; Kinier, P.; Herren, W. The design and characterization of polyspecific antibodies for simultaneous targeting of multiple disease mediators J. Mol. Biol. 2009, 393, 672-692 10.1016/j.jmb.2009.08.032
28. Bezabeh, B.; Fleming, R.; Coffman, K.; Leow, C. C.; Gibson, N.; Wilson, S.; Stover, C. K.; Wu, H.; Gao, C.; Dimasi, N. Design and characterization of a novel tetravalent bispecific antibody. Submitted.
29. Schuck, P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling Biophys. J. 2000, 78, 1606-1619 10.1016/S0006-3495(00)76713-0
30. Friedman, L. M.; Rinon, A.; Schechter, B.; Lyass, L.; Lavi, S.; Bacus, S. S. et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 1915-1920 10.1073/pnas.0409610102
31. Loisel, S.; André, P. A.; Golay, J.; Buchegger, F.; Kadouche, J.; Cérutti, M.; Bologna, L.; Kosinski, M.; Viert, D.; Bischof Delaloye, A.; Berthou, C.; Mach, J. P.; Boumsel, L. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia Mol. Cancer 2011, 10, 42 10.1186/1476-4598-10-42
32. Nejatollahi, F.; Jaberipour, M.; Asgharpour, M. Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells Tumor Biol. 2014, 35, 7887-7895 10.1007/s13277-014-1854-8
33. Pedersen, M. W.; Jacobsen, H. J.; Koefoed, K.; Hey, A.; Pyke, C.; Haurum, J. S.; Kragh, M. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy Cancer Res. 2010, 70, 588-597 10.1158/0008-5472.CAN-09-1417
34. Pedersen, M. W.; Jacobsen, H. J.; Koefoed, K.; Dahlman, A.; Kjaer, I.; Poulsen, T. T.; Meijer, P. J.; Nielsen, L. S.; Horak, I. D.; Lantto, J.; Kragh, M. Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance Mol. Cancer Ther. 2015, 14, 669 10.1158/1535-7163.MCT-14-0697
35. Scheuer, W.; Friess, T.; Burtscher, H.; Bossenmaier, B.; End, J.; Hasmann, M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models Cancer Res. 2009, 69, 9330-9336 10.1158/0008-5472.CAN-08-4597
36. Kiewlich, D.; Zhang, J.; Gross, C.; Xia, W.; Larsen, B.; Cobb, R. R.; Biroc, S.; Gu, J. M.; Sato, T.; Ligh, D. R.; Heitner, T.; Willuda, J.; Vogel, D.; Monteclaro, F.; Citkowicz, A.; Roffler, S. R.; Zajchowski, D. A. Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth Neoplasia 2006, 8, 18-30 10.1593/neo.05544